Krystal Biotech, Inc. (KRYS) Tops Q4 EPS by 1c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of ($1.25), $0.01 better than the analyst estimate of ($1.26).

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results